Delivery Order SPE2DR25D3201-SPE2DR26FT4PR
- Not listed
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $7,541.90 by the Defense Logistics Agency (DLA) on December 9, 2025, with an ultimate completion date of December 10, 2025. This competitive award, which carries no set-aside designation, is for the supply of Vemlidy 25 mg tablets in quantities of 30 units. The contract employs firm fixed pricing and is classified as a delivery order, indicating it derives from a larger indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $7,265.45 on October 15, 2025, for the supply of Vemlidy 25 mg tablets in quantities of 30. This non-competitive delivery order is a firm fixed price contract with a completion date of October 16, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a firm fixed-price delivery order valued at $5,726.30 by the Defense Logistics Agency (DLA) on October 28, 2025, with an ultimate completion date of October 29, 2025. The contract calls for delivery of Vemlidy 25 mg tablets (30-count units), an antiviral medication used in hepatitis B treatment. This award represents a competitive, non-set-aside contract and will be...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on September 24, 2025, for the supply of Vemlidy 25 mg tablets (30-count units) under a firm fixed-price contract valued at $23,466.99. The contract is a non-set-aside award funded by the Defense Logistics Agency's Medical Supply Chain, with a completion date of September 25, 2025. This delivery order represents a specific fulfillment under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,018.04 to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets (30-count units) on December 9, 2025, with completion scheduled for December 10, 2025. This firm fixed-price delivery order carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency (DLA) on August 29, 2025, for Vemlidy 25 mg tablets in a quantity of 30 units. The contract is valued at $7,802.23 with a firm fixed price and an ultimate completion date of September 2, 2025. This is a non-set-aside, competitively awarded delivery order issued under AmerisourceBergen's substantial Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,025.85 to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets in quantities of 30 tablets. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of December 8, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $5,823.97 to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets in a quantity of 30 units. The contract, awarded on November 7, 2025, with an ultimate completion date of November 10, 2025, is structured as a firm fixed price delivery order with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $6,057.57 to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets (30-count units) with a completion date of December 2, 2025. This firm fixed-price contract, awarded December 1, 2025, represents a non-set-aside competitive award to support federal pharmaceutical procurement needs. AmerisourceBergen's Conshohocken, Pennsylvania facility will serve as the place of performance for this delivery order. This delivery...
- The Defense Logistics Agency awarded a competitive delivery order to AmerisourceBergen Drug Corp, valued at $1,047.30, for the supply of Vemlidy 25 mg tablets (30-count units). The award was issued on November 28, 2025, with an ultimate completion date of December 1, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion...
- SPE2DR25D3201Indefinite Delivery Contract
- SPE2DR25D3201-SPE2DR26FT4PRDelivery Order
AmerisourceBergen Drug Corp was awarded a delivery order valued at $6,202.38 by the Defense Logistics Agency (DLA) on December 10, 2025, for the supply of Vemlidy 25 mg tablets (30-count units). This is a firm fixed price, non-set-aside contract with an ultimate completion date of December 11, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical support vehicle valued through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, holds a significant role in the federal medical procurement supply chain, serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive portfolio of competitively awarded federal contracts demonstrates its capability to fulfill diverse medical supply needs, ranging from specialty medications and brand-name drugs to vaccines and medical devices across multiple therapeutic domains. The DLA plans to establish Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, positioning AmerisourceBergen as a key strategic partner in supporting military and federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.2k | 12/9/25 |